Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garrett

Showing results (291-300 of 330) with videos related to

Pageof 33
Sort By:
Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Oncology Practice|January 11, 2023
Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-AssessmentCarmen Guerra, Alice Pressman, Patricia Hurley, et al.
JCO Oncology Practice|August 29, 2023
Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data QualityJoseph M Unger, Hillary Stires, Laura A Levit, et al.
Journal of Immunotherapy and Precision Oncology|May 9, 2024
Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR)Abdul-Rahman Jazieh, Adda Bounedjar, Hikmat Abdel-Razeq, et al.
Science Translational Medicine|March 1, 2013
Mutant HSP70 reverses autoimmune depigmentation in vitiligoJeffrey A Mosenson, Andrew Zloza, John D Nieland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementEdward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAjjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
JCO Precision Oncology|February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyCarmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Pageof 33

Showing results (291-300 of 330) with videos related to

Sort By:
Pageof 33
Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Oncology Practice|January 11, 2023
Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-AssessmentCarmen Guerra, Alice Pressman, Patricia Hurley, et al.
JCO Oncology Practice|August 29, 2023
Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data QualityJoseph M Unger, Hillary Stires, Laura A Levit, et al.
Journal of Immunotherapy and Precision Oncology|May 9, 2024
Impact of COVID-19 on Management and Outcomes of Oncology Patients: Results of MENA COVID-19 and Cancer Registry (MCCR)Abdul-Rahman Jazieh, Adda Bounedjar, Hikmat Abdel-Razeq, et al.
Science Translational Medicine|March 1, 2013
Mutant HSP70 reverses autoimmune depigmentation in vitiligoJeffrey A Mosenson, Andrew Zloza, John D Nieland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementEdward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2021
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyAjjai S Alva, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
JCO Precision Oncology|February 14, 2024
Sunitinib in Patients With Breast Cancer With <i>FGFR1</i> or <i>FGFR2</i> Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyCarmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Pageof 33